Pediatric Exclusivity Could Be Out-Licensed To Other Sponsors, FDA Suggests
This article was originally published in The Tan Sheet
Executive Summary
Congress should consider allowing pediatric exclusivity periods to be licensed to other sponsors as a mechanism for promoting pediatric study of drug products that do not have patent protection or exclusivity, FDA's pediatric exclusivity status report suggests.